Trial reportHealth and quality of life outcomes2013
Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Trial report in Health and quality of life outcomes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Trial
- Trial
- A Text Message Intervention to Minimize the Time Burden of Cancer Care.NEJM catalyst innovations in care delivery · 2025Article
- Article
- Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China.Health and quality of life outcomes · 2023Article
- Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.Frontiers in endocrinology · 2023Article
- Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.Frontiers in public health · 2023Article
- Do Drug Accessibility and OOP Burden Affect Health-Related Quality of Life of Patients With Chronic Diseases? - EQ-5D-5L Evaluation Evidence From Five Districts in China.Frontiers in public health · 2021Article
- Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease.Frontiers in oncology · 2021Article
- Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.Health and quality of life outcomes · 2020Article
- Mapping the Strengths and Difficulties Questionnaire onto the Child Health Utility 9D in a large study of children.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Article
- Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.The patient · 2018Article
- Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2018Article
- A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy.The European journal of health economics : HEPAC : health economics in prevention and care · 2018Article
- Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.PharmacoEconomics - open · 2018Review
- A preliminary prediction model for potentially guiding patient choices between breast conserving surgery and mastectomy in early breast cancer patients; a Dutch experience.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018Article
- Concurrent chemoradiotherapy degrades the quality of life of patients with stage II nasopharyngeal carcinoma as compared to radiotherapy.Oncotarget · 2017Article
- Article
- Systematic review of health state utility values for economic evaluation of colorectal cancer.Health economics review · 2016Review
- Development and validation of quality of life scale of nasopharyngeal carcinoma patients: the QOL-NPC (version 2).Health and quality of life outcomes · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo help facilitate economic evaluations of oncology treatments, we mapped responses on cancer-specific instrument to generic preference-based measures.
methodsCancer patients (n = 367) completed one cancer-specific instrument, the FACT-G, and two preference-based measures, the EQ-5D and SF-6D. Responses were randomly divided to form development (n = 184) and cross-validation (n = 183) samples. Relationships between the instruments were estimated using ordinary least squares (OLS), generalized linear models (GLM), and censored least absolute deviations (CLAD) regression approaches. The performance of each model was assessed in terms of how well the responses to the cancer-specific instrument predicted EQ-5D and SF-6D utilities using mean absolute error (MAE) and root mean squared error (RMSE).
resultsPhysical, functional, and emotional well-being domain scores of the FACT-G best explained the EQ-5D and SF-6D. In terms of accuracy of prediction as measured in RMSE, the CLAD model performed best for the EQ-5D (RMSE = 0.095) whereas the GLM model performed best for the SF-6D (RMSE = 0.061). The GLM predicted SF-6D scores matched the observed values more closely than the CLAD and OLS.
conclusionOur results demonstrate that the estimation of both EQ-5D and SF-6D utility indices using the FACT-G responses can be achieved. The CLAD model for the EQ-5D and the GLM model for the SF-6D are recommended. Thus, it is possible to estimate quality-adjusted life years for economic evaluation from studies where only cancer-specific instrument have been administered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.